Condition
CABOTEGRAVIR
Total Trials
3
Recruiting
0
Active
0
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
1Total
P 2 (1)
Trial Status
Not Yet Recruiting2
Withdrawn1
Clinical Trials (3)
Showing 3 of 3 trials
NCT07402044Not Yet RecruitingPrimary
CABOTEGRAVIR/LENACAPAVIR DUAL LONG ACTING THERAPY (COHORT IMEA 074)
NCT06657885Phase 2Withdrawn
CAbotégravir LENacapavir DUal Long Acting
NCT07131826Not Yet Recruiting
The Quality of Life and Viral Control Effect of AIDS Patients After Long-acting Injection of Cabotegravir and Rilpivirine
Showing all 3 trials